Ctrl

K

Table of contents

Expand All Topics

Membranoproliferative glomerulonephritis

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of membranoproliferative glomerulonephritis are prepared by our editorial team based on guidelines from the Kidney Disease: Improving Global Outcomes Foundation (KDIGO 2021).
1

Diagnostic investigations

Evaluation for etiology, IC-MPGN: as per KDIGO 2021 guidelines, evaluate patients with immune complex-mediated glomerulonephritis for underlying disease:
Situation
Guidance
Infections
HCV and HBV infections, endocarditis, infected ventriculoatrial shunt, visceral abscess, leprosy, meningococcal meningitis
Autoimmune diseases
SLE, Sjögren's disease, rheumatoid arthritis, mixed connective tissue disease
Monoclonal gammopathy
Plasma cell or B-cell disorder
Other
Fibrillar glomerulonephritis, idiopathic
E
Show 2 more
Create free account

More topics in this section

  • Evaluation for etiology (C3G)

Medical management

Management of immune complex-mediated MPGN: as per KDIGO 2021 guidelines, focus on the treatment of the underlying pathologic process as the initial approach to management when the cause of immune complex-mediated glomerulonephritis is determined.
E
Show 7 more

More topics in this section

  • Management of C3 glomerulopathy